Study Detail
If you join a clinical trial with us, you’ll receive patient-centered care and open communication during the study and beyond. Your comfort is our priority.
TG Therapeutics Study for Relapsing Multiple Sclerosis
The ENHANCE Study is looking for people with relapsing forms of multiple sclerosis (RMS) who are currently being treated with Disease Modifying Therapy (DMT) to take part.
This 48-week study is to determine the efficacy and safety when switching from your current DMT to ublituximab and to determine if giving it over a shorter infusion time is safe and tolerable. If transitioning from another anti-CD20 therapy you may be eligible for a modified dosing schedule to eliminate the initial 150 mg dose of ublituximab.
Ublituximab is approved by the US Food and Drug Administration (FDA) with the name BRIUMVI®, for adults with relapsing forms of multiple sclerosis. In this study, ublituximab is considered investigational because the initial dose of ublituximab may be different than the initial dose currently approved by the FDA, and some doses may be administered over shorter periods of time than the time currently approved by the FDA. If transitioning from another anti-CD20 therapy you may be eligible for a modified dosing schedule to eliminate the initial 150 mg dose of ublituximab.
